Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Corcept Therapeutics's annualizedNet Income for the quarter that ended in Mar. 2026 was $-127.0 Mil. Corcept Therapeutics's average total tangible assets for the quarter that ended in Mar. 2026 was $825.8 Mil. Therefore, Corcept Therapeutics's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was -15.38%.
The historical rank and industry rank for Corcept Therapeutics's Return-on-Tangible-Asset or its related term are showing as below:
CORT'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 5.74 Med: 20.85 Max: 89.27
Current: 5.74
During the past 13 years, Corcept Therapeutics's highest Return-on-Tangible-Asset was 89.27%. The lowest was 5.74%. And the median was 20.85%.
CORT's Return-on-Tangible-Asset is ranked better than 87.97% of 1413
companies
in the Biotechnology industry
Industry Median: -35.75
vs CORT: 5.74
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Corcept Therapeutics Return-on-Tangible-Asset Related Terms
Corcept Therapeutics Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Corcept Therapeutics's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CORT vs PRAX, IBRX, NUVL: Return-on-Tangible-Asset Comparison
For the Biotechnology subindustry, Corcept Therapeutics's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Corcept Therapeutics Return-on-Tangible-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Corcept Therapeutics's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Corcept Therapeutics's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of -15.38% mean?
Corcept Therapeutics (CORT) has a Return-on-Tangible-Asset of -15.38% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Corcept Therapeutics and its competitors. Over the past decade, Corcept Therapeutics' Return-on-Tangible-Asset has ranged from 5.74 to 89.27. According to the industry distribution chart, Corcept Therapeutics ranks #170 out of 1413 companies in the Biotechnology industry, placing it in the top 12%.
Is Corcept Therapeutics' Return-on-Tangible-Asset too high?
Corcept Therapeutics' current Return-on-Tangible-Asset is -15.38%. Over the past 10 years, this metric has ranged from a low of 5.74 to a high of 89.27. Based on the distribution chart, Corcept Therapeutics ranks #170 out of 1413 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Corcept Therapeutics has a GF Score™ of 85/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Corcept Therapeutics' Return-on-Tangible-Asset compare to PRAX and IBRX?
According to the Biotechnology industry distribution chart, Corcept Therapeutics ranks #170 out of 1413 companies for Return-on-Tangible-Asset. This places Corcept Therapeutics in the top 12% of its industry — outperforming the majority of peers. Historically, Corcept Therapeutics' own Return-on-Tangible-Asset has ranged from 5.74 to 89.27 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Corcept Therapeutics and its competitors. Corcept Therapeutics's current Return-on-Tangible-Asset is -15.38%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corcept Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Corcept Therapeutics (CORT) is currently considered Significantly Overvalued. The stock's GF Value™ is $62.56, compared to a current price of $91.61 — trading 46.4% above its estimated fair value. The current Return-on-Tangible-Asset is -15.38%. Corcept Therapeutics' overall GF Score™ is 85/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Corcept Therapeutics (CORT), the current Return-on-Tangible-Asset is -15.38% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Corcept Therapeutics (CORT) Overvalued in 2026?
Based on GuruFocus' analysis, Corcept Therapeutics stock appears to be overvalued.
The current stock price of $91.61 is trading 46.4% above its estimated GF Value™ of $62.56.
GuruFocus considers Corcept Therapeutics to be Significantly Overvalued.
Key valuation signals for CORT:
Return-on-Tangible-Asset: -15.38%
GF Value™: $62.56 vs. price of $91.61 (46.4% above fair value)
No single metric tells the full story. See the CORT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
85GF Score
Get the complete analysis for CORT
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CORT has been successfully added to your 
